Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

Related Experiment Videos

M Hanefeld1

  • 1Centre for Clinical Studies, GWT Technical University, Dresden, Germany. hanefeld@gwtonline-zks.de

International Journal of Clinical Practice. Supplement
|June 28, 2007
PubMed

Insights

Early combination therapy for type 2 diabetes, using sulfonylureas and thiazolidinediones, can preserve beta-cell function and improve glycaemic control. This approach optimizes long-term outcomes by addressing insulin resistance and protecting pancreatic beta-cells.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) is marked by progressive decline in glycemic control due to beta-cell dysfunction.
  • Current management often involves escalating therapy from monotherapy to combination treatments, including insulin.
  • Preserving beta-cell function is a critical goal for long-term T2D management.

Purpose of the Study:

  • To evaluate the rationale for early combination therapy in T2D management.
  • To assess the benefits of combining sulfonylureas and thiazolidinediones.
  • To explore the impact on beta-cell preservation and glycemic control.

Main Methods:

  • Review of pharmacological mechanisms of sulfonylureas and thiazolidinediones.
  • Analysis of their effects on insulin secretion, insulin sensitivity, and beta-cell function.
  • Consideration of combination therapy in early stages of T2D.

Main Results:

  • Sulfonylureas stimulate insulin secretion; thiazolidinediones improve insulin sensitivity.
  • Thiazolidinediones demonstrate beta-cell protective effects.
  • Combination therapy offers synergistic improvements in glycemic control and insulin resistance.

Conclusions:

  • Combining thiazolidinediones with sulfonylureas provides a strong therapeutic rationale for T2D.
  • This combination may be particularly beneficial in early T2D stages to preserve beta-cell function.
  • Early, aggressive combination therapy optimizes long-term glycemic control and reduces cardiovascular risk factors.

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...